Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Helius Medical Technologies ( (HSDT) ) is now available.
Helius Medical Technologies announced that its Board of Directors approved an amendment to the 2022 Equity Incentive Plan, increasing the number of shares of common stock by 20% of the Fully Diluted Shares. This amendment was approved by stockholders on May 23, 2025, and resulted in an increase to 7.1 million shares available under the plan as of June 16, 2025, following a public offering.
The most recent analyst rating on (HSDT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Helius Medical Technologies stock, see the HSDT Stock Forecast page.
Spark’s Take on HSDT Stock
According to Spark, TipRanks’ AI Analyst, HSDT is a Underperform.
Helius Medical Technologies scores low due to significant financial challenges, characterized by ongoing losses and negative cash flow. Technical analysis confirms bearish momentum, with the stock being oversold. The valuation is unattractive with a negative P/E ratio and no dividend yield. Without positive earnings call or corporate events data to offset these negatives, the stock faces a challenging outlook.
To see Spark’s full report on HSDT stock, click here.
More about Helius Medical Technologies
Average Trading Volume: 5,580,423
Technical Sentiment Signal: Strong Sell
Current Market Cap: $190.3K
For detailed information about HSDT stock, go to TipRanks’ Stock Analysis page.